Autonomix Medical has regained compliance with the minimum bid price requirement set by Nasdaq. The company received a notification from the exchange confirming that its stock has met the necessary criteria for continued listing. This development secures the company's position on the Nasdaq Capital Market.

The notification follows a period during which the company's stock price fell below the $1.00 minimum threshold. Nasdaq rules provide a grace period for companies to regain compliance, which Autonomix Medical has successfully utilized. The company's shares will continue to trade without interruption.

Compliance Details

The specific rule in question is Nasdaq Listing Rule 5450(a)(1), which mandates a minimum bid price of $1.00 per share. Failure to comply can result in delisting. The following table outlines the key compliance metrics:

Regulatory Context

Autonomix Medical initially received a deficiency notice from Nasdaq when its closing bid price fell below the required level for 30 consecutive business days. The company had a 180-day compliance period to rectify the issue. The recent notification confirms that the stock has maintained a closing bid price of at least $1.00 for 10 consecutive business days, thereby satisfying the rule's conditions.

This compliance restoration removes the immediate threat of delisting and allows the company to focus on its operational objectives. Investors can continue to trade Autonomix Medical shares on the Nasdaq Capital Market under the ticker symbol AMIX.

Autonomix Medical, Inc. announced the development of a proprietary standalone neural sensing platform following preclinical results showing evidence of the ability to identify renal neural activity and detect real-time changes in neural activity following intervention. The platform is expected to target expansion into the multi-billion-dollar cardiovascular market with a potential Class II diagnostic regulatory path. The architecture supports future expansion into denervation, including renal, pulmonary, cardiac, splanchnic, and other nerve-targeted applications, with potential compatibility across multiple denervating technologies.

The standalone neural sensing platform will be built on the same core sensing technology as Autonomix's lead pancreatic cancer pain program and is being developed in parallel with that initiative. This enables a capital-efficient expansion into cardiology, which represents a significant new therapeutic market opportunity. In recent preclinical studies, changes in blood pressure were induced and reproducible changes were observed in recorded neural signals in real time.

Additional studies are underway to further characterize the relationship between these signals and sympathetic nerve activity. These findings highlight the potential for a more precise, feedback-driven or closed-loop approach to renal denervation. This may address a longstanding challenge in the field, where the absence of direct physiological feedback can contribute to variability in treatment outcomes.

Renal denervation has emerged as a promising treatment option for patients with uncontrolled or resistant hypertension and represents a large and growing market. Autonomix believes that incorporating neural sensing into the procedure, which would enable physicians to identify active nerve targets, guide therapy delivery, and confirm treatment effect in real time, may offer meaningful differentiation in this space with improved procedural consistency, precision, and efficacy.

While Autonomix’s initial focus for the standalone neural sensing platform will be renal denervation, the underlying architecture is designed to be indication-agnostic and is applicable wherever autonomic nerve activity drives disease. The Company believes this positions the platform for future expansion into pulmonary nerve applications, ganglionated plexi for atrial fibrillation, splanchnic nerve therapies, and other indications where precise nerve detection and procedural confirmation could meaningfully improve outcomes.

"These preclinical results support what we believe is a fundamental advantage of our platform – to see the nerve, guide the therapy, and confirm the result in real time," said Brad Hauser, Chief Executive Officer of Autonomix. "The standalone platform strategy opens a capital-efficient path into cardiology and beyond, and a potentially more focused development and regulatory pathway."

Autonomix intends to pursue additional preclinical studies and evaluate further expansion in a staged manner that builds on the regulatory and clinical foundation established through renal denervation. Autonomix’s sensing technology has been presented at leading interventional cardiovascular scientific forums, including Transcatheter Cardiovascular Therapeutics, Cardiovascular Research Technologies, and EuroPCR. Autonomix was recently recognized with one of CRT 2026’s Best Cardiovascular Innovation Awards.